ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
Stock Information for ProPhase Labs Inc.
Please wait while we load your information from QuoteMedia.
More Recent News About ProPhase Labs Inc.
ProPhase Labs to Host 2022 Year End Financial Results Conference Call on Tuesday, March 28, 2023 at 11:00 a.m. Eastern Time
ProPhase Labs' Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome Sequencing DNA Test
ProPhase Labs Announces Collaboration with mProbe, Inc. and Mayo Clinic for the Continuing Development of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science